Kornimate/medical-research-clean huggingface dataset:
remnants of conception after suction evacuation of missed abortion

Conditions: Miscarriage

Summary: all women admitted for surgical evacuation of missed abortion after failure of medical treatment from june 2016 underwent transvaginal sonography immediately after completion of the procedure as judged by the operator to ensure absence of remnants.

women indicated for surgical evacuation of missed abortion up to 12 weeks were included. standard surgical evacuation of uterus by suction followed by sharp curettage under general anaesthesia were done for all cases. when the operator judged the procedure as complete, transvaginal sonography was done by dedicated sonographer using portable ultrasound machine in theatre. if remnants were detected the procedure was repeated till the cavity seen empty.

Eligibility criteria:
inclusion criteria: multiparous. have missed abortion up to 12 weeks gestational age by dating. failed medical evacuation. consented for the procedure. exclusion criteria: suspicion of sepsis. suspected molar pregnancy. previous evacuation trial. abnormal uterus like fibroids. -

Keywords: remnants of conception
pilot study on the effects of neuromuscular taping in parkinson's disease patients

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is a degenerative disorder characterized by a symptom triad consisting on: tremor, rigidity and bradykinesia . to these symptoms it is often added postural alteration that can stand in two different attitudes, such as the camptocormia and the syndrome of pisa . progressing in its evolution, pd becomes increasingly disabling, making it difficult or even impossible daily activities such as washing or dressing.the abnormal posture, with alteration of the limbs, the neck and trunk, is a recurring feature in pd, with a frequency of about 30%. between 2% and 12.3% are more severe abnormalities such as camptocormia, the syndrome of pisa and the anterocollis. several studies disease plug in neuromuscular taping technique (nmt) among rehabilitative tools in degenerative neurological syndromes. to the best of our knowledge, no applications were found in pd. therefore, the current study was designed to evaluate quantitatively the effects of the nmt intervention on the trunk kinematics during standing position. more specifically, this study aims to compare the trunk kinematic variables of patients with pd who were treated with effective nmt versus those of the subjects who received only the pharmacological treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic pd by united kingdom brain bank criteria * no other significant neurological or orthopedic problems * age between 55 and 80 years * mds-updrs item 3.13 posture between mild and moderate (definite flexion, scoliosis or leaning to one side) * patient able to walk independently or with minimal assistance for 10 meters * medical treatment for parkinson's disease must be stable for at least two weeks prior to inclusion, and during the study. during the study, the dosage of anti-parkinsonian drug treatment should not change, if it is not deemed necessary by the investigator. exclusion criteria: * disability to understand instructions required by the study (informed consent test of comprehension) * primarily wheelchair bound * skin abrasions * sensitive skin

Keywords: parkinson's disease neuromuscular taping trunk posture kinematic rehabilitation
an evaluation of navina mini, a new trans-anal irrigation (tai) device in children and adolescents

Conditions: Bowel Dysfunction

Summary: the study is designed to deliver further information on clinical benefit, patients' satisfaction, and perception of handling and to confirm safety of navina mini when used in children and adolescents.

this is an uncontrolled, prospective, multicentre post-market clinical follow-up investigation that will enroll male and female children /adolescents with a need for low-volume transanal irrigation (tai) as judged by the investigator or designee. a total of 27 subjects in need of low-volume tai will be recruited from 2-3 sites in sweden and will be treated with navina mini as per product intended purpose and per instruction of use. participating subjects will perform three visits during the clinical investigation and will be followed for a total of four (4) to six (6) weeks. the study is designed to deliver further information on clinical benefit, patients' satisfaction, and perception of handling and to confirm device safety when used in children and adolescents.

Eligibility criteria:
inclusion criteria: * signed informed consent * male and female children/adolescents between 3 and 17 years of age at the time of inclusion * diagnosis of at least one of the following: * functional constipation not well treated with oral laxatives * functional fecal incontinence, either retentive or non-retentive (fnrfi: functional non-retentive fecal incontinence) not well treated with oral laxatives * neurogenic bowel dysfunction due to spinal abnormalities and/or spinal cord injury or cerebral palsy * patient with sequelae of anorectal malformations to hirschsprung disease * fecal incontinence (fi) due to iatrogenic injury including tumor surgery sequelae * symptom duration of \> 3 months * subject and/or their legally designated representative can communicate in written and oral swedish language exclusion criteria: * children/adolescents previously treated with, or currently in need of, high volume tai, i.e., volume \> 250 ml * confirmed pregnancy at the time of enrollment * participating in another clinical investigation interfering with this investigation * subjects with an active, symptomatic, inflammatory bowel disease, radiation proctitis, and or active perianal fistula disease * rectal bleeding of uncertain origin or active hemorrhoidal bleeding * \< 6 months after anal or colorectal surgery * ongoing anti-coagulant therapy (i.e., noacs, heparin, warfarin) * ischemic colitis * active anal fissure * inability to use the product or anyone to assist in its usage (hand function assessment) * person not suitable for the investigation according to the investigator's judgment
a study to learn about the first and later lines of medicines in treating people with metastatic renal cell carcinoma (mrcc).

Conditions: Metastatic Renal Cell Carcinoma

Summary: the purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mrcc. the study includes participants who: * are 18 years old or above and have mrcc * took medicines that use the bodies immunity to fight against cancer as their first choice of treatment * took other medicines after taking the above first choice of treatment this is a study that looks into the data collected through a particular database from selected academic clinical sites participating in this study. the data of interest include: * the length of time between the start of a patient's treatment and the end of treatment * the length of time between the start of treatment and death * physician assessment of a patient's response to treatment we will compare the experiences of people receiving different combinations of treatments and see if there are any differences in the effectiveness of these medicines.


Eligibility criteria:
inclusion criteria: * diagnosed with mrcc * age 18 years or over at the time of mrcc diagnosis * received io combination treatment in 1l such as receiving ipilimumab + nivolumab or an axitinib-based regimen (ie, axitinib + pembrolizumab or axitinib + avelumab) as 1l * received subsequent treatments following 1l (e.g., 2l, 3l) * actively treated at an imdc clinical center (to avoid incomplete data) exclusion criteria: - there are no exclusion criteria for this study

Keywords: kidney cancer metastatic renal cell carcinoma (mrcc) international metastatic renal cell carcinoma database consortium (imdc) immunotherapy.
aroplatin and gemcitabine in patients with advanced pancreatic cancer resistant to standard therapies

Conditions: Pancreatic Neoplasms

Summary: this study is a phase i/ii study. in phase i of this study, the objective is to determine the maximum tolerated dose (mtd) of combination therapy with aroplatin and gemcitabine (gemzar®) in subjects with unresectable, locally advanced and/or metastatic pancreatic cancer. in phase ii, the primary objective is to evaluate survival after therapy with aroplatin and gemcitabine at the identified mtd in subjects with unresectable, locally advanced and/or metastatic pancreatic cancer. secondary objectives are to evaluate the severity and quantity of adverse events and determine the proportion of non-progressors and the progression-free interval.

phase i primary objective: * determine the maximum tolerated dose (mtd) of combination therapy with aroplatin and gemcitabine (gemzar®) in subjects with unresectable, locally advanced and/or metastatic pancreatic cancer. phase ii primary objective: * evaluate survival after therapy with aroplatin and gemcitabine at the mtd in subjects with unresectable, locally advanced and/or metastatic pancreatic cancer. phase ii secondary objective: * evaluate the severity and quantity of adverse events and determine the proportion of non-progressors and the progression-free interval.

Eligibility criteria:
inclusion criteria * pancreatic cancer (ajcc stage ii-iv); * unresectable cancer; * measurable disease (recist criteria); * no prior therapy; * ecog score 0-2 * life expectancy greater then or equal to three months; * adequate hematopoietic, liver and renal function; * women of child-bearing potential must have negative urine/serum pregnancy test; * signed written informed consent; * subjects must be willing to be followed during the course of the treatment/observation and follow-up. exclusion criteria: * prior therapy for pancreatic cancer; * previously diagnosed brain metastases if symptomatic and requiring active therapy; * other cancers within the last five years, with the exception of adequately treated cone-biopsied in-situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin; * any serious concomitant medical or mental illness requiring intense therapy and interfering with participation in this study * primary or secondary immunodeficiency, or use of corticosteroids immunosuppressive medication; * women must not be pregnant or breast-feeding; * participation in any clinical trial involving investigational drugs within one month from enrollment into the present study.

Keywords: pancreatic cancer neoplasms pancreatic pancreas cancer pancreas neoplasms pancreatic tumor pancreas tumor unresectable metastatic refractory
a study of laparoscopic middle hepatic vein guidance and traditional anatomic hemihepatectomy

Conditions: Hepatocellular Carcinoma

Summary: the study, entitled "rct study of laparoscopic middle hepatic venous guidance versus conventional ananatomical hemihepatectomy", was designed to compare the efficacy of two different ananatomical hemihepatectomy procedures under laparoscopy.

backgroud \& aim:hepatectomy is the main way to treat all kinds of liver surgical diseases, which can be divided into anatomic hepatectomy and non-anatomic hepatectomy.among them, anatomic hepatectomy is suitable for primary liver cancer, hepatolithiasis and other benign and malignant diseases;it can be divided into hepatic venous guidance and non-hepatic venous guidance hepatectomy (traditional ananatomical hepatectomy).the aim of this study was to observe and compare the perioperative period and follow-up results of the two different laparoscopic surgical resection methods, and to provide high-level evidence-based medicine evidence for the selection of surgical methods for laparoscopic anatomical hemihepatectomy.

Eligibility criteria:
inclusion criteria: 1. the site was limited to the patients who were suitable for dissecting hemihepatectomy； 2. the type of disease was limited to hepatocellular carcinoma； 3. the patients were generally able to tolerate anesthesia, the liver reserve function was good, and the patients were suitable for laparoscopic surgery； 4. child-pugh grade a, no severe liver cirrhosis, portal hypertension, no extrahepatic and extrahepatic metastasis and main vascular invasion； 5. the subjects who participated in this study indicated that they were willing to accept the two surgical methods and agreed to be randomly divided into groups during the operation； 6. 18 ≤ age ≤ 70, male or female. exclusion criteria: 1. preoperative liver function child-pugh grade b or c; 2. patients with poor general condition and could not tolerate pneumoperitoneum or anesthesia; 3. patients with severe liver cirrhosis, portal hypertension and lesions invading liver porta; 4. patients with other treatment methods such as radio frequency ablation in addition to dissecting hepatectomy; 5. repeated abdominal operations resulting in severe abdominal adhesion, unable to perform laparoscopic hepatectomy; male and female are not limited

Keywords: laparoscopic middle hepatic vein hepatocellular carcinoma
olanzapine vs. comparator and placebo in the treatment of patients with bipolar i disorder

Conditions: Bipolar Disorder

Summary: the goals of this study are: a. to determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania. b. to assess the safety of olanzapine and any side effects that might be associated with it, as well as the quality of life and functioning of patients treated with olanzapine. c. to assess how olanzapine compares to divalproex.


Eligibility criteria:
inclusion criteria: * you must be 18 to 65 years old. * you must have a diagnosis of bipolar i disorder and must be experiencing a manic or mixed (symptoms of mania and depression occurring together) episode. * you must be able to visit the doctor's office as scheduled for 15 weeks. * all female patients must test negative for pregnancy and, if of childbearing potential, must be using a medically accepted means of contraception. exclusion criteria: * you have rapid cycling bipolar disorder, or are having hallucinations or delusions, or are feeling suicidal. * you are pregnant or breastfeeding * you have a history of: inadequately controlled diabetes; heart disease; narrow angle glaucoma; low white blood cell or platelet count; have a positive test result for human immunodeficiency virus (hiv+); or any other serious, unstable illnesses as judged by the study physician.
effectiveness of preoxygenation with positive airway pressure: a comparison of the supine and 25° head up position

Conditions: Intubation;Difficult

Summary: several techniques such as positive airway pressure and head-up tilt during preoxygenation have shown to prolong non-hypoxic apnea period compared to conventional technique. however, uniform recommendations have not yet been made. therefore, in the present study the investigators attempted to find out the effect of combination of 5 cmh2o cpap and 25° head up position during preoxygenation.

in this study 60 non-obese healthy adult patients were divided into three groups; group c receiving preoxygenation in conventional technique, group s receiving preoxygenation with 5 cmh2o cpap and group h receiving preoxygenation in 25° head-up position with 5 cmh2o cpap. after 3 min of preoxygenation, anesthesia was induced and trachea intubated. after confirming the tracheal intubation by direct visualization, all patients were left apneic in supine position with the tracheal tube exposed to atmosphere till the spo2 dropped to 92%. the primary outcome compared between the groups was the non-hypoxic apnoeic period (time to fall spo2 to 92%).

Eligibility criteria:
inclusion criteria: * adult patients of asa physical status i and ii undergoing surgery under general anaesthesia exclusion criteria: * anticipated difficult mask ventilation/ intubation * individuals with significant cardiorespiratory or cerebrovascular disease * pregnant ladies * patient with history of epilepsy * body mass index \>25 kg/m2 * hemoglobin \<8 gm/dl * patients who were non-ambulant for \>24 h, having spo2 \< 97% while breathing in room air * phobia to facemask.

Keywords: apnea cpap preoxygenation
level of iliopsoas tenotomy in ddh surgery

Conditions: Developmental Dysplasia of the Hip (DDH)

Summary: the goal of this clinical trial is to compare the postoperative clinical outcome of iliopsoas tenotomy in open reduction operation for developmental dysplasia of the hip. the main aim is to compare the postoperative clinical outcome of division of iliopsoas tendon at two levels, proximally at the pelvic brim and distally just above the lesser trochanter.

all the patients with ddh included in the current study underwent open reduction of their dislocated hip through the anterior approach. none of the included patients underwent hip surgery through the medial approach. for the proximal level of psoas tenotomy at the pelvic brim, the hip was slightly flexed to relax the iliopsoas muscle; the iliacus muscle fibers were retracted anteriorly until the deeply seated posteromedially psoas tendon was isolated and transected. for the distal level of iliopsoas tenotomy just above the lesser trochanter, the thigh was put in the position of faber (flexion, abduction, and external rotation). a curved right-angle hemostatic clamp was used to retract and bring the iliopsoas tendon into the field. then, the tendinous fibers were transected.

Eligibility criteria:
inclusion criteria: * children with ddh. * required open reduction of their hip problem. exclusion criteria: * patients who underwent hip surgery without the need for sectioning the iliopsoas tendon. * children with mental retardation who were not cooperative in the assessment of the hip flexion strength.

Keywords: hip developmental dysplasia of the hip surgical treatment iliopsoas tenotomy randomized clinical trial
ledipasvir/sofosbuvir fixed-dose combination in adults with nosocomial genotype 1 hcv infection

Conditions: Hepatitis C

Summary: this study is to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (ldv/sof) fixed-dose combination (fdc) in adults with nosocomial genotype 1 hepatitis c virus (hcv) infection.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) greater than or equal to 18 kg/m\^2. * hcv rna greater than or equal to 1000 iu/ml at screening. * documented acquisition of nosocomial genotype 1 hcv infection within 36 months from the screening visit. * screening laboratory values within predefined thresholds. * use of two effective contraception methods if female of childbearing potential or sexually active male. * healthy according to medical history and physical examination with the exception of hcv diagnosis. exclusion criteria: * unstable cardiac disease including subjects with active angina pectoris and/or hospitalization for a cardiac condition within 24 weeks prior to screening. * prior exposure to an hcv ns5a inhibitor. * pregnant or nursing female. * infection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv). * history of solid organ transplantation. * current or prior history of clinical hepatic decompensation. * history of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol. * known hypersensitivity to ldv, sof, or formulation excipients.

Keywords: 7977 5885 gs-7977 gs-5885 sof ldv sofosbuvir ledipasvir fdc
rifaximin in patients with diabetic gastroparesis

Conditions: Crohn Disease; Diabetic Gastroparesis

Summary: researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.


Eligibility criteria:
inclusion criteria * men and women adult patients, aged 18-75, with diabetic gastroparesis * diagnosis of diabetic gastroparesis will have been made previously using a combination of symptoms (e.g., nausea, vomiting, bloating, early satiety, abdominal pain), the absence of mechanical obstruction, and delayed gastric emptying using a 4-hour, solid phase scintigraphic study (ges; \> 20% remaining at 4 hours) exclusion criteria * prior surgery to the stomach or esophagus * known mechanical obstruction of the gi tract * current or recent (\< 4 weeks) use of opioids * current/active use of cannabis * current or recent (\< 4 weeks) use of antibiotics * current or recent use of antifungal agents (\< 4 weeks) * prior treatment with rifaximin (\< 1 year) * uncontrolled diabetes with a hgba1c \> 12 * severe uncontrolled or untreated anxiety or depression.
demographic characteristics and psychosocial health of transgender people

Conditions: Gender Dysphoria

Summary: to study demographic characteristics of subjects referred to endocrine care for gender dysphoria and their psychosocial health


Eligibility criteria:
inclusion criteria - person having received complete information on the organization of the research and willing to participate to research exclusion criteria: - lack of data in the patients' records
a study to evaluate efficacy and safety of a fixed combination ocular insert in participants with open-angle glaucoma or ocular hypertension

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to determine if a combination of two drugs (bimatoprost and timolol) delivered to the surface of the eye over 10 weeks is better at lowering intraocular pressure (iop) than either of the drugs delivered alone.


Eligibility criteria:
key inclusion criteria: * written informed consent * at least 18 years of age * diagnosis in both eyes of either primary open-angle glaucoma (poag) or ocular hypertension * best corrected-distance visual acuity score equivalent to 20/80 or better * stable visual field * central corneal thickness between 490 - 620 micrometers inclusion criteria at the randomization visit: * iop for each eye is ≥ 23 mmhg at t=0hr, ≥ 20 mmhg at t=4hr and t=8hr. * inter-eye iop difference of ≤ 5.0 mmhg at t=0hr, t=4hr and t=8hr. * iop for each eye is ≤ 30 mmhg at t=0hr, t=4hr and t=8hr. key exclusion criteria: * any known contraindication to prostaglandin analog (latanoprost, travoprost, bimatoprost, tafluprost) or timolol * a cardiac or pulmonary condition that in the opinion of the investigator would contraindicate the use of a topical beta-blocker * use of any agents known to have a substantial effect on iop during planned study period (e.g. beta-blockers) * cup-to-disc ratio of greater than 0.8 * significant risk of angle closure due to pupil dilation, defined as a shaffer classification of less than grade 2 based on gonioscopy * ocular, orbital, and/or eyelid surgery of any type within the past six (6) months from screening date * laser surgery for glaucoma / ocular hypertension on one (1) or both eyes within the last six (6) months * past history of any incisional surgery for glaucoma at any time * past history of corneal refractive surgery * corneal abnormalities that would interfere with accurate iop readings with an applanation tonometer * current participation in an investigational drug or device study or participation in such a study within 7 days of screening * inability to adequately evaluate the retina * subjects who will require contact lens use during the study period. * subjects who currently have punctal occlusion * pregnant, lactating or of child-bearing potential and not using a medically acceptable form of birth control